News

Read about Benitec in the news, events and developments in the RNAi industry below. For details of Benitec's announcements to the ASX, read details in our Investor Centre.

2017

Benitec Mid-Year Shareholder Update 05-Jul-2017
Nature: OPMD data published in Nature Communications 31-Mar-2017
BioWorld: Aussie firm Benitec gets new life via Nantworks deal 21-Feb-2017

2016

Seeking Alpha : Benitec Bio to collaborate with NantVentures in cancer-focused R&D 24-Oct-2016
Fierce BioTech : Soon-Shiong swoops in on Benitec for PhII gene-silencing data 24-Oct-2016
Gen News : Benitec, NantVentures Launch Oncology R&D Collaboration 24-Oct-2016
In vivo OPMD data presented at BSGCT meeting 15-Apr-2016
Benitec Comments on CSHL IP Activity 13-Apr-2016

2015

Benitec’s CEO interviewed by Alan Kohler for Eureka Report 01-May-2015
CSIRO maintains foundational patent for RNAi gene silencing technology – CSIRO 02-Mar-2015
Institutional Investors Wary of Early Stage Biotech Firms - The Australian 23-Feb-2015
Benitec’s CEO featured in February The CEO Magazine 01-Feb-2015
Benitec’s progress with programs and partnering featured in MergerMarket 27-Jan-2015

2014

PR Newswire: Global RNAi therapeutics market to reach $1.2b by 2020 09-Sep-2014
Bioshares: “Evidence of ddRNAi therapy correctly activating liver cells” in HCV clinical trial 05-Sep-2014
The Scientist: The Second Coming of RNAi 01-Sep-2014
Benitec's CBO speaks with Sky Business News 17-Aug-2014
Benitec’s licensee Calimmune featured on PBS NewsHour on HIV/AIDS 07-Feb-2014
Benitec features in QANTAS ‘The Australian Way’ magazine 06-Jan-2014

2013

The Australian: Biotech firm offers remedy for carmaker void 19-Dec-2013
Benitec in BRW’s Top 5 Trend ‘Biotech boat lifted in buoyant markets’ in 2013 17-Dec-2013
Benitec's CEO on New York-based O Six News 16-Dec-2013
Benitec’s CEO on 4BC ‘Health & Well being’ 15-Dec-2013
Bioshares: Benitec’s technology risk ‘very high’ but ‘very likely exceeded by potential’ 13-Dec-2013
Lodge Partners says FDA review is ‘low risk’ and recommends ‘buy’ 02-Dec-2013
Benitec in ‘7 biotech stocks with bounding share prices’ – The Bull 18-Nov-2013
Calimmune's CSO presents HIV clinical trial update to Benitec Sydney Shareholder Session 15-Nov-2013
MergerMarket says Benitec could see partnership interest next year 13-Nov-2013
Benitec featured in the Ahead Of The Curve magazine 01-Oct-2013
TT-034 selected for pre-eminent Liver Disorders conference 05-Aug-2013
Renub Research: Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide 29-Jul-2013
Hepatitis C Research & News: FDA puts ‘partial hold’ on Vertex study 26-Jul-2013
Benitec raises $7m for hep C treatment after 6 year patent war (BRW) 17-Jun-2013
Advance Abstract: Local injection of lentivirus encoding LINGO-1 shRNA promotes functional recovery in rats 17-Jun-2013
Freehills Update : US Supreme Court Decision on Myriad’s Gene Patent- Implications for Australian Applicants 14-Jun-2013
TT-034 Clinical Trial Protocol - RAC Jun 2013 12-Jun-2013
Yahoo Finance: uniQure to Receive EUR 2.5 Million Grant for RNAi Gene Therapy for Huntington's Disease 21-May-2013
UCSD selected as site for HCV ‘in-human’ trials 17-Apr-2013
RAC submission moves HCV closer to the clinic 16-Apr-2013
Genable gains Orphan Drug status for eye treatment 15-Apr-2013
Former CEO of Cephalon Joins Benitec’s Board 11-Apr-2013

2012

Benitec Presents at US 6th Annual Pain Therapeutics Summit 13-Dec-2012
BLT Ausbiotech Presentation Nov 2012 31-Oct-2012
ddRNAi – The New Therapeutic Revolutions? Benitec Presentation Australian Microcap Investment Conference 17-Oct-2012
Presentation San Jose Pain Therapeutics Summit & San Francisco Investor Forum 02-Oct-2012
Benitec Strategy Update: Pathways to Revenue 25-Sep-2012
Hepatitis B Program Meeting Review China 3-6 Sept 2012 06-Sep-2012
Benitec teams with Stanford University on Chronic Pain Research 13-Aug-2012
Chief Investigators Group Update 01-Jun-2012
Technology Update: ddRNAi - The New Therapeutic Revolution? 14-May-2012